ByTrending Posts
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu…
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine…
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care…
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral…
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could the Medtronic–Abbott Partnership Shift the Future of…
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…
Could Medtronic’s Hugo™ Robotic System Redefine Hernia Surgery…
Key Highlights A Landmark Clinical Study for Robotic Hernia SurgeryMedtronic’s Enable Hernia Repair trial is the first Investigational…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line…
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma…
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Can AI-Powered Platforms from Certara, Recursion, and Charles…
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Trending Posts
Latest Stories
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind,…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including…
Gallery
